重症患者侵袭性念珠菌病:基本概念与未来方向
该综述聚焦ICU患者侵袭性念珠菌病(IC),包括念珠菌血症和深部感染。念珠菌血症约占ICU血流感染的20%,腹腔内念珠菌病是最常见的深部感染形式,主要影响外科ICU患者。白念珠菌仍是最常见菌种,但非白念珠菌近十年更流行,耳念珠菌等易致ICU暴发的菌种值得关注。临床征象与细菌感染无法区分,识别高危患者是选择正确诊断方法的关键。传统血培养和组织培养敏感性欠佳且耗时,新型分子检测更快但受成本和缺乏外部验证限制。确诊后一线治疗为棘白菌素类,部分患者可换用唑类,新型抗真菌药正在测试用于多重耐药念珠菌。
要点
- 念珠菌血症约占ICU患者血流感染的20%,腹腔内念珠菌病是最常见深部感染形式,主要影响外科ICU患者。
- 白念珠菌是最常见菌种,但非白念珠菌近十年更流行,耳念珠菌等易致ICU暴发的菌种值得关注。
- IC临床征象与细菌感染无法区分,识别高危患者是选择正确诊断方法的关键。
- 血培养和组织培养敏感性欠佳且耗时,延迟IC确诊;新型分子检测更快但受成本和缺乏外部验证限制。
- 确诊IC后一线治疗为棘白菌素类抗真菌药,部分患者可换用唑类;新型抗真菌药正在测试用于多重耐药念珠菌。
适用人群与场景
- ICU患者,包括内科ICU和外科ICU患者;腹腔内念珠菌病主要影响外科ICU患者。
处置流程与药物剂量
- 确诊IC后一线治疗为棘白菌素类抗真菌药。
- 部分患者可换用唑类抗真菌药。
- 新型抗真菌药正在测试用于治疗多重耐药念珠菌菌种。
研究设计与关键结果
- 综述指出念珠菌血症约占ICU患者血流感染的20%,腹腔内念珠菌病是最常见深部感染形式,主要影响外科ICU患者。
- 白念珠菌是最常见菌种,但非白念珠菌近十年更流行;耳念珠菌和其他易致ICU暴发的菌种值得关注。
- IC临床征象与细菌感染无法区分;传统血培养和组织培养敏感性欠佳且耗时,延迟确诊;新型分子检测更快但受成本和缺乏外部验证限制。
- 确诊IC后一线治疗为棘白菌素类,部分患者可换用唑类;新型抗真菌药正在测试用于多重耐药念珠菌。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 综述强调识别IC高危患者是选择正确诊断方法的关键,因临床征象与细菌感染无法区分。
- 传统培养敏感性欠佳且耗时,新型分子检测可能支持及时抗真菌治疗,但其使用受成本和缺乏外部验证限制。
- 确诊IC后一线使用棘白菌素类,部分患者可换用唑类;多重耐药念珠菌可考虑新型抗真菌药(尚在测试中)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
TOPIC IMPORTANCE: Invasive candidiasis (IC) is a common complication in patients in ICUs. IC can be divided into bloodstream infections (candidemia) and deep-seated infections. Candida infections are associated with high mortality and longer hospital stays. Moreover, the emergence of Candida auris and other species prone to cause ICU outbreaks highlights the importance of this pathogen.
REVIEW FINDINGS: Candidemia represents about 20% of bloodstream infections in ICU patients, whereas intraabdominal candidiasis, the most common form of deep-seated infection, predominantly affects surgical ICU patients. Regarding species distribution, Candida albicans is the most common species; however, non-albicans species have become more prevalent in the past decade. Clinical signs of IC are indistinguishable from bacterial infections; therefore, identifying patients at risk of IC is key to choosing the right diagnostic approach. Diagnostic tests include conventional methods such as blood and tissue cultures; however, they have suboptimal sensitivity and are time-dependent, which delay the confirmation of IC. As a result, newer molecular tests offer faster results; however, their use remains limited by cost and lack of external validation. Once IC is diagnosed, first-line treatment is with echinocandin antifungals, with the option of switching to azoles in selected patients. In addition, new antifungals are being tested to treat multidrug-resistant Candida species.
SUMMARY: Our results show that Candida species is a significant pathogen in ICU patients and has a heterogeneous clinical presentation. Conventional diagnostic methods lack sufficient sensitivity to detect IC at an early stage. New diagnostic strategies may support timely antifungal therapy.
参考来源
- Pérez MA, Hoffmann WJ, Pérez JC, et al. Invasive Candidiasis in Critically Ill Patients: Fundamental Concepts and Future Directions. Chest. 2025. PMID: 41478495. doi:10.1016/j.chest.2025.12.020
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。